Certainly something can be learned by such presentations, but I believe even if the trial were unblinded before the presentation, she couldn't go much beyond whatever was announced as top line data. Why? Because the company would want to present that information at a major conference, like SNO. Once data has been presented, even at a minor presentation, major conferences like SNO, ASCO, etc don't want it simply to be repeated, they want information presented at their conferences that is truly new to those in attendance.
I believe Dr. Liau has previously been very positive about DCVax-L, and continues to be, but she'll cooperate with the company to present major new data at major conferences. It's certainly my hope that they unblind before SNO, but if not, while ASCO might be the next major conference, there are others not quite as large where the presentation could be made. If I remember correctly, the cutoff for Abstracts at ASCO is in February, though an accepted Abstract can be revised for a period of time. Data actually presented at these major conferences can be right up to the minute, but the Abstract has to present enough to be scheduled for presentation, and how it's to be presented will also be based on what's in the abstract. All I'm suggesting is that it's a very important document, even if much is updated after its submission.
We've got to be getting close to the period where the program for SNO is released, hopefully then we'll learn a lot more about what NWBO will be presenting, I believe Dr. Liau is speaking there as well, but that's not specifically tied to an Abstract on DCVax-L.
Gary
